articleCirculationAug 31, 2008Closed access

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

St. Michael's Hospital · Radboud University Nijmegen · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

BACKGROUND: Patients with diabetes mellitus (DM) are at high risk for recurrent cardiovascular events after acute coronary syndromes, in part because of increased platelet reactivity. The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed an overall reduction in ischemic events with more intensive antiplatelet therapy with prasugrel than with clopidogrel but with more bleeding. We compared prasugrel with clopidogrel among subjects with DM in TRITON-TIMI 38. METHODS AND RESULTS: We classified 13 608 subjects on the basis of preexisting history of DM and further according to insulin use.…

Citation impact

757
total citations
FWCI
48.34
Percentile
100%
References
42
Citations per year

Authors

12

Topics & keywords

Keywords
  • Prasugrel
  • Medicine
  • Clopidogrel
  • Internal medicine
  • TIMI
  • Myocardial infarction
  • Cardiology
  • Diabetes mellitus
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.